Skip to content

Baby ABS (Abdominal Binder Study)

Baby ABS (Abdominal Binder Study) : Impact of Abdominal Binder Use on Abdominal Wall Development in Premature Infants Requiring CPAP Support

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07049900
Enrollment
40
Registered
2025-07-03
Start date
2025-01-22
Completion date
2027-04-30
Last updated
2026-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature, Premature Lungs, Rectus Abdominis, Ventilator Lung; Newborn

Keywords

bCPAP, CPAP, NAVA CPAP

Brief summary

The primary outcome of this study is to determine if the use of the FDA-approved DandleLion NeoBellyBand increases the thickness of the rectus abdominis muscle in premature babies receiving continuous positive pressure ventilation, leading to infants reaching full oral feedings at an earlier corrected gestational age.

Interventions

DEVICENeoBelly Band

The DandleLion NeoBellyBand (NBB) is an FDA listed Class 1 medical device that is 510k exempt and is categorized under therapeutic medical binders. This device is indicated to be used while the infant is receiving CPAP support in order to reduce CBS. The NBB is made of a medical-grade blend of fabric and foam that is latex and neoprene-free and is reported as safe to use on premature infant skin. There are two sizes available and the outer fabric is attached with adjustable Velcro. It is a single baby use and may be hand washed and reused. This device is currently in use in multiple NICUs around the country, and as it has already been FDA-approved for the purpose of our investigation.

Sponsors

University of Minnesota
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Weeks to 31 Weeks
Healthy volunteers
No

Inclusion criteria

* Premature viable neonates with corrected gestational age of 22-31 weeks * Anticipated to require non-invasive continuous positive pressure ventilation including bCPAP, CPAP, and NAVA CPAP for a minimum of 2 weeks either on their first trial of CPAP or after extubation.

Exclusion criteria

* Outside of gestational age at birth * Umbilical lines * Genetic condition or neuromuscular anomaly * Known abdominal anomaly * Non-viable neonates and neonates with uncertain viability who are not anticipated to be able to survive with standard NICU care. * Surgical intervention on the abdominal wall, such as gastroschisis or history of surgical NEC * Compromised skin integrity of abdominal wall * Any condition in the opinion of the investigator that would risk the data integrity or collection of the study

Design outcomes

Primary

MeasureTime frameDescription
Change in thickness of the rectus abdominis muscle8 weeksThickness measured by ultrasound

Countries

United States

Contacts

CONTACTAndrea Charara, MD
chara061@umn.edu(612) 626-0644
PRINCIPAL_INVESTIGATORSarah Ramel, MD

University of Minnesota

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 12, 2026